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Abstract Introduction This X-VeRT (eXplore the efﬁcacy and safety of once-daily oral riVarox-
aban for the prevention of caRdiovascular events in patients with nonvalvular aTrial
ﬁbrillation scheduled for cardioversion) substudy evaluated the effects of treatment
with rivaroxaban or a vitamin-K antagonist (VKA) on levels of biomarkers of coagulation
(D-dimer, thrombin–antithrombin III complex [TAT] and prothrombin fragment [F1.2])
and inﬂammation (high sensitivity C-reactive protein [hs-CRP] and high-sensitivity
interleukin-6 [hs-IL-6]) in patients with atrial ﬁbrillation (AF) who were scheduled for
cardioversion and had not received adequate anticoagulation at baseline (deﬁned as, in
the 21 days before randomization: no oral anticoagulant; international normalized
ratio <2.0 with VKA treatment; or <80% compliance with non-VKA oral anticoagulant
treatment).
Methods Samples for biomarker analysis were taken at baseline (n¼958) and
treatment completion (42 days after cardioversion; n¼918). The inﬂuence of clinical
characteristics on baseline biomarker levels and the effect of treatment on changes in
biomarker levels were evaluated using linear and logistic models.
Results Baseline levels of some biomarkers were signiﬁcantly associated with type of
AF (D-dimer and hs-IL-6) and with history of congestive heart failure (hs-CRP, D-dimer,
and hs-IL-6). Rivaroxaban and VKA treatments were associated with reductions
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Introduction
Atrialﬁbrillation (AF) is themost common cardiac arrhythmia.
The prevalence of AF is approximately 3% among adults aged
20years or older but increases with age to more than 15%
among adults aged 80years or older.1,2 Pharmacological or
electrical cardioversion can be used to restore sinus rhythm
rapidly. However, cardioversion is associated with a peripro-
cedural risk of thromboembolic events of up to 9% in patients
who have not received anticoagulants.3–5 To minimize this
risk, immediate initiation of anticoagulation is recommended
in all patients scheduled for cardioversion.5
AF is associated with a prothrombotic state; elevated levels
of the circulating coagulation biomarkers D-dimer, prothrom-
bin fragment 1þ2 (F1.2), and thrombin–antithrombin III com-
plex (TAT) have been detected in patients with AF.6 Vitamin-K
antagonist (VKA) therapy has been shown to signiﬁcantly
suppress levels of D-dimer, F1.2, and TAT.7 There is evidence
that inﬂammation is a driver of the prothrombotic state and
that it plays a signiﬁcant role in the pathogenesis of AF.8–11
Elevated levelsof the inﬂammationbiomarkershigh-sensitivity
interleukin-6 (hs-IL-6) and high-sensitivity C-reactive protein
(hs-CRP) have been observed in patients with AF.11,12 Inﬂam-
matory mediators including ILs are thought to promote
arrhythmogenesis as a result of structural and contractile
remodeling of the atria and endocardium.11 There have also
been reports of a correlation between inﬂammatorymediators
and the duration of AF and success of cardioversion, suggesting
a possible predictive role for these biomarkers.11,12
Rivaroxaban is a non-VKA oral anticoagulant (NOAC) that
directly inhibits factor Xa. There is evidence to suggest that, in
addition to its role in coagulation, factor Xa has proinﬂamma-
tory effects. For example, a reduction in the levels of hs-CRPhas
been demonstrated in patients with AF who received enoxa-
parin (an indirect factorXa inhibitor) as bridging therapybefore
cardioversion.13 It is, therefore, possible that inhibitionof factor
Xa with rivaroxaban may induce anti-inﬂammatory responses
and have a protective effect on the vascular endothelium, in
addition to anticoagulant actions.14 The effects of rivaroxaban
on selected biomarkers of coagulation have previously been
demonstrated in patients with venous thromboembolism.15,16
However, the effects of rivaroxaban on a combination of
coagulation and inﬂammation biomarkers in patients with AF
undergoing cardioversion have not yet been fully evaluated.
The X-VeRT (eXplore the efﬁcacy and safety of once-daily
oral riVaroxaban for thepreventionofcaRdiovascular events in
patients with nonvalvular aTrial ﬁbrillation scheduled for
cardioversion) study investigated the efﬁcacy and safety of
rivaroxaban compared with a VKA for thromboprophylaxis in
patients with non-valvular AF scheduled for cardioversion.
Patientswith hemodynamically signiﬁcantmitral valve steno-
sis orprostheticheart valveswereexcluded.17,18This substudy
of X-VeRT evaluated the effects of rivaroxaban and VKAs on
biomarkers of coagulation (D-dimer, TAT, and F1.2) and bio-
markers of inﬂammation (hs-IL-6 and hs-CRP) in the same
patient population.
Materials and Methods
X-VeRT Study Design
X-VeRT was a prospective, randomized, open-label, parallel-
group,active-controlled,multicenter, andphase-IIIbstudy.17,18
In brief, patients with hemodynamically stable nonvalvular AF
(of more than 48hours or unknown duration) who were
scheduled for electrical or pharmacological cardioversion
were randomized in a 2:1 ratio to receive rivaroxaban or a
VKA. Patients randomized to receive rivaroxaban were given a
once-daily oral dose of 20mg (reduced to 15mg in patients
with a creatinine clearance of 30–49mL/min), and those ran-
domized to receive a VKA (warfarin or another VKA based on
local standard of care) were treatedwith the aim of achieving a
target international normalized ratio (INR) of 2.5 (range,
2.0–3.0). A parenteral anticoagulant drug could be adminis-
tered in addition to VKA therapy, especially before cardiover-
sion, until the target INR was reached.
One of two cardioversion strategies was selected before
randomization at the discretion of the investigator in accor-
dance with the protocol.18 Patients treated with an early
cardioversion strategy received rivaroxaban or usual VKA
therapy for 1 to 5 days before the procedure and 42 days
thereafter. Patients treated with a delayed cardioversion
strategy received rivaroxaban or a VKA for 3 to 8 weeks
before the procedure and 42 days thereafter.18
Biomarker Substudy: Objectives and Patient
Population
The overall objectives of the biomarker substudy were to
evaluate biomarkers of coagulation (D-dimer, TAT, and F1.2)
and inﬂammation (hs-CRP and hs-IL-6) in patients receiving
rivaroxaban or a VKA in the X-VeRT study. The speciﬁc aims
were to (1) evaluate the inﬂuence of treatment with rivar-
oxaban or a VKA on changes in biomarker levels from
baseline to the end of treatment; (2) investigate the inﬂuence
of pretreatment with oral anticoagulants (OACs) andmedical
from baseline in levels of D-dimer (32.3 and 37.6%, respectively), TAT (28.0 and
23.1%, respectively), hs-CRP (12.5 and 17.9%, respectively), and hs-IL-6 (9.2 and
9.8%, respectively). F1.2 levels were reduced from baseline in patients receiving a
VKA (53.0%) but not in those receiving rivaroxaban (2.7%).
Conclusion Anticoagulation with rivaroxaban reduced levels of key inﬂammation and
coagulation biomarkers to a similar extent as VKAs, with the exception of F1.2. Further
investigation to conﬁrm the value of these biomarkers in patients with AF is merited.
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history on biomarker levels at baseline; and (3) explore the
predictive and prognostic value of the selected biomarkers.
Patients in the modiﬁed intention-to-treat (mITT) popula-
tion of X-VeRT (which excluded patients in whom a left atrial
thrombus was detected before cardioversion) were eligible for
inclusion in the biomarker substudy. At baseline, samples for
biomarkeranalysiswereonly taken frompatientsconsidered to
havehad inadequateoral anticoagulationbefore randomization
because, in thosepatients, biomarker levelswere assumedtobe
the least inﬂuenced by prior anticoagulation. These patients
included the following: (1) those who had been treated with a
VKA in the 21 days before randomization but had an INRof less
than 2.0 at any time in that period; (2) those who had been
treatedwith aNOAC in the 21 days before randomization but in
whom compliance was less than 80% in that period; and (3)
those who had not received OACs in the 21 days before
randomization or had never received any OAC prior to the
study. Patients were deﬁned as untreated or naive to OACs if
they had not taken a VKA or NOAC in the 6 weeks before
entering the study.
Blood Sample Collection
Venous blood samples were taken at the screening visit, and
then again at the end of treatment visit (or at the time of early
discontinuation of study treatment). Depending on the
cardioversion treatment strategy, the end of treatment
sample was taken 43 (þ4) days (early cardioversion) or 63
to 98 (þ4) days (delayed cardioversion) after the ﬁrst intake
of study drug. For the end of treatment sample, patients had
to have taken the last dose of study drug within 24hours of
the sampling for biomarkers.
Biomarker Analysis
A laboratory manual, detailing instructions for the handling
and shipment of blood samples, was provided to each site.
Blood samples were immediately centrifuged for plasma
preparation, frozen, and stored at 20°C or below before
being shipped on dry ice for analysis. All biomarkers
were analyzed by Covance CLS (Indianapolis, Indiana,
United States). Concentrations of the coagulation biomarkers
D-dimer, F1.2, and TAT were measured in citrated plasma
using immunoturbidimetry for D-dimer (INNOVANCE
D-dimer assay kit [intra- and interassay precision 1.5–7.8%
and 2.2–7.9% coefﬁcient of variation [CV], respectively;
Siemens Healthcare Diagnostics, Newark, Delaware, United
States], Siemens BCS, and BCS XP) and enzyme-linked
immunosorbent assay (ELISA) for F1.2 and TAT (Enzygnost
F1þ2 kit [intra- and interassay precision 3.6–5.5% and
4.4–11.2% CV, respectively] and Enzygnost TAT kit [intra-
and interassay precision 3.1–6.0% and 6.0–9.0% CV, respec-
tively], Siemens Healthcare Diagnostics Products, Marburg,
Germany). Reference ranges are less than 0.59mg/L ﬁbrino-
gen equivalent units (FEU) for D-dimer, 69 to 229 pmol/L for
F1.2 and 1.0 and 4.1 µg/L for TAT.
Concentrationsof the inﬂammationbiomarkers hs-CRPand
hs-IL-6 were measured in serum or ethylenediaminetetra-
acetic acid (EDTA) plasma using immunonephelometry for
hs-CRP (N hsCRP reagent [Siemens Healthcare Diagnostics,
Deerﬁeld, Illinois, United States] and Siemens BN II Nephelom-
eter [intra- and interassay precision 2.3–4.4% and 2.1–5.7% CV,
respectively]) andELISA forhs-IL-6 (QuantikineHumanhs-IL-6
Immunoassay kit [intra- and interassay precision 6.9–7.8% and
6.5–9.6% CV, respectively], R&D Systems, Minneapolis, Minne-
sota, United States). Reference ranges are 0.287mg/dL or below
for hs-CRP and less than 12.50 pg/mL for hs-IL-6.
Clinical Events
To determine the prognostic/predictive value of the biomark-
ers, the relationship between biomarker levels and major and
nonmajor bleeding events were evaluated. All bleeding events
were adjudicated. Major and nonmajor bleeding events were
deﬁned according to the International Society on Thrombosis
and Hemostasis criteria.19 The relationship between biomark-
er levels at baseline and time to cardioversion and whether or
not cardioversion was successful was also examined. Cardio-
version was considered successful if restoration of normal
sinus rhythm was achieved after the ﬁrst electrical or phar-
macological cardioversion during the study.
Statistical Methods
All analyses were performed using SAS version 9.4 or later
versions (SAS Institute Inc., Cary, North Carolina, United
States) and R version 3.1.0 or later versions.20
Thenumberofpatients included in this substudywasbased
on feasibility and clinical judgment rather than on statistical
considerations relating to the biomarker identiﬁcation objec-
tives. Relationships between biomarker levels and variables of
interest were analyzed by linear and logistic regression mod-
els; a signiﬁcanceα level of 0.05wasused forallmodels.Allﬁve
biomarkers were characterized by a heavily skewed distribu-
tion; therefore, the datawere log-transformed prior to regres-
sion analysis.
Factors Inﬂuencing Biomarker Levels at Baseline
Relevantdemographiccharacteristics (outof sex, race, age, and
bodymass index [BMI]) for thebaseline level ofeachbiomarker
were identiﬁed by means of multivariable linear regression
models. Potentially relevantdemographiccharacteristicswere
selected for each biomarker based on the minimal Akaike
information criterion (AIC). The selected demographic charac-
teristics were considered as covariates in linear regression
models for the analysis of the relationship between biomarker
baseline levels and medical history and prior OAC intake, to
control for any inﬂuence that theymayhavehadonthestudied
biomarkers.
Relationship between Biomarker Levels at Baseline and
Clinical Events during the Study
The prognostic or predictive potential of biomarker levels at
baseline was assessed by logistic models for the binary end-
points (bleeding events) and by a linear model for the (log-
transformed) time to cardioversion. Relevant covariates were
chosen from the pool of potential covariates (demographic
characteristics, medical history, cardioversion strategy, prior
OAC intake, treatment, and CHADS2 [congestive heart failure
(HF), hypertension, age75 years, diabetes mellitus, prior
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stroke, thromboembolism, or transient ischemic attack (TIA)]
score) by means of a stepwise AIC forward selection. The
resulting base models were then expanded by the set of
biomarkers (as main effects or in interaction with treatment),
which led to an overall best model for the respective endpoint.
Thiswasalsoaccomplishedbya stepwiseAIC forward selection
(i.e., only those biomarkers that led to an expected improve-
ment in endpoint prediction were added to the model).
The AIC-based variable selection that was applied in these
analyses is an established method to preﬁlter relevant
variables for an endpoint of interest.21 Variables that do
not improve the prediction accuracy for the respective
endpoint are excluded to decrease the number of parameters
and, hence, improve the stability of the results in the
multivariable analyses.
Inﬂuence of Treatment and Other Factors on Changes in
Biomarker Levels from Baseline to End of Treatment
Biomarker changes from baseline to end of treatment were
analyzed and compared between the two treatment arms by
linear regression models, adjusted for biomarker baseline
levels, and the differences in treatment duration that were
induced by the study design. The effects of medical history,
prior OAC intake, cardioversion strategy, and cardioversion
success on the biomarker changes were investigated by
adding the respective information to the models as main
effects and in interaction with the treatment.
Results
Patients
In the X-VeRT study, 1,504 patients in total were random-
ized to receive either rivaroxaban (1,002 patients; 66.6%) or
a VKA (502 patients; 33.4%).17 The mITT population of
1,470 patients (rivaroxaban group, 978 patients; VKA
group, 492 patients) included 1,101 patients who were
untreated or naive to OACs or had received inadequate OAC
treatment before randomization and were, therefore, eligi-
ble for inclusion in the biomarker substudy (►Fig. 1).17
Blood samples for biomarker analysis were collected
from a total of 958 patients at baseline and 918 patients
at the end of treatment. An overview of the number of
measurements available for each biomarker is provided
in ►Supplementary Table S1, and a comparison of baseline
characteristics between the two treatment arms is given
in ►Supplementary Table S2.
Fig. 1 Patient ﬂow and overview of biomarker collection. EoT, end of treatment; hs-CRP, high-sensitivity C-reactive protein; mITT, modiﬁed
intention-to-treat; OAC, oral anticoagulant.
aPatients in the mITT population in whom a left atrial thrombus was not diagnosed during transesophageal echocardiography performed before
the ﬁrst planned cardioversion.
bReasons for missing results, for example, specimen not frozen, insufﬁcient quantity, hemolysis.
cAvailability of samples based on available hs-CRP measurements; end of treatment samples could still be collected from patients without a
baseline sample.
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Factors Inﬂuencing Biomarker Levels at Baseline
Patient Characteristics
Relevant demographic characteristics (out of sex, race,
age, and BMI) for the baseline level of each biomarker
are displayed in ►Table 1. Overall, only a small fraction
of biomarker variability (between 1.6% [TAT] and 11.2%
[D-dimer]) was explained by patient characteristics. The
relevant demographic variables for each biomarker were
considered as covariates for the following analyses of
pretreatment and medical history.
Pretreatment with OACs
In patients who had received pretreatment with OACs,
baseline levels of F1.2, D-dimer and TAT were lower than
in patients whowere untreated or naive to OACs (F1.2: 87.23
vs. 214.99 pmol/L, p<0.001; D-dimer: 0.20 vs. 0.40mg/L
FEU, p<0.001; and TAT: 4.48 vs. 5.71 ug/L, p¼0.003).
Pretreatment with OACs did not signiﬁcantly inﬂuence
baseline levels of hs-CRP or hs-IL-6 (►Fig. 2 [F1.2 only]
and ►Supplementary Table S3).
Medical History
In patientswith a history of congestiveHF,meanbaseline levels
of hs-CRP, D-dimer, and hs-IL-6 were signiﬁcantly higher than
in patients with no history of congestive HF (hs-CRP: 3.47 vs.
2.29mg/L, p<0.001; D-dimer: 0.41 vs. 0.32mg/L FEU,
p¼0.001; hs-IL-6: 3.41 vs. 2.37 pg/mL, p<0.001; ►Fig. 3
[hs-CRP only] and ►Supplementary Table S4).
High-CHADS2 scores were associated with signiﬁcantly
higher baseline levels ofD-dimer andhs-IL-6 than lowCHADS2
scores (D-dimer: 0.31, 0.32, and 0.36mg/L FEU for low, moder-
ate, and high-CHADS2 scores, respectively, p<0.001; hs-IL-6:
2.27, 2.48, and2.73pg/mL for low,moderate, andhigh-CHADS2
scores, respectively, p<0.001; ►Supplementary Table S5).
Therewas a signiﬁcant negative relationship between base-
line levels of D-dimer and increasing persistence of AF (0.43,
0.39, 0.28, and 0.24mg/L FEU for ﬁrst-diagnosed, paroxysmal,
persistent, and long-standing persistent AF, respectively,
p<0.001; ►Supplementary Table S6). A similar negative
relationship was also found between the persistence of AF
and levels of hs-IL-6, although baseline levels of hs-IL-6 were
highest in patients with paroxysmal AF (2.71, 2.96, 2.36, and
2.03 pg/mL for ﬁrst-diagnosed, paroxysmal, persistent, and
long-standing persistent AF, respectively, p<0.001; ►Fig. 4
[D-dimer only] and ►Supplementary Table S6).
Relationship between Biomarker Levels at Baseline
and Clinical Events during the Study
Bleeding Events
TheAIC-basedanalysis revealedhs-CRPbaselinelevels together
with thepresenceofaprior strokeandapriorTIAas thebest set
of potential predictors for bleeding events. However, none of
these variables was signiﬁcantly related to the occurrence
of bleeding events (►Table 2), indicating no prognostic value
of the biomarkers or of any of the clinical or demographic
covariates.
Table 1 Proportion of variability in biomarker baseline levels
explained by demographic variablesa
Biomarker Sex Race Age BMI Explained
variability (%)
hs-CRP x x x 5.6
D-dimer x x 11.2
hs-IL-6 x x 9.2
F1.2 x x 1.7
TAT x x 1.6
Abbreviations: BMI, body mass index; F1.2, prothrombin fragment
1þ 2; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6, high-sensitivity
interleukin-6; TAT, thrombin–anti-thrombin III complex.
aRelevant set of demographic variables for each biomarker (marked by an
“x”) was selected by AIC (Akaike’s information criterion) optimization.
Fig. 2 Inﬂuence of pretreatment with OACs on F1.2 levels at baseline.
F1.2, prothrombin fragment 1þ 2; OAC, oral anticoagulant; ULOQ,
upper limit of quantiﬁcation.
Note: Upper lines of the box denote the upper quartiles, midlines
denote the medians and lower lines denote the lower quartiles;
crosses denote the geometric means, and upper and lower lines
denote maximum andminimum values, excluding outliers (i.e., values
that are >1.5 times the interquartile range further apart from the
box).
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Cardioversion Success
The analysis of the success of the cardioversion did not reveal
any additional beneﬁt of biomarkers. The AIC-optimal model
contained thehistoryofdiabetesmellitus (decreasedchancefor
a successful cardioversion, odds ratio [OR]¼0.58, p¼0.042),
treatment (increased chance if treated with rivaroxaban, OR
¼1.81, p¼0.009), and race (decreased chance for Asian
patients in comparison with White patients, OR¼0.34,
p¼0.001) as signiﬁcant predictors (►Table 2).
Time to First Cardioversion under Treatment
The AIC-optimal model for the log-transformed time to
cardioversion contained all biomarkers with the exception
of D-dimer, in addition to the cardioversion strategy, treat-
ment, history of arterial hypertension, history of diabetes
mellitus, and prior MI (►Table 2). Even though all of the
contained biomarkers were signiﬁcantly related to the time
to cardioversion, the amount of explained variability could
only be increased by 1.1% points in comparison with the
model that contained only the cardioversion strategy as a
predictor (88.1 vs. 87.0%), which indicates no relevant addi-
tional value of the biomarkers.
Additional descriptive statistics for the biomarker base-
line levels in relation to the clinical events described in this
section are provided in ►Supplementary Table S7.
Inﬂuence of Treatment with Rivaroxaban or a VKA on
Biomarker Levels
Levels of D-dimer, TAT, hs-CRP, and hs-IL-6 decreased from
baseline to the end of treatment in both the rivaroxabangroup
and in the VKA group, with the greatest reductions of 32.3% in
the rivaroxaban group and 37.7% in the VKA group being
observed for D-dimer (►Fig. 5; ►Supplementary Table S8).
After adjusting for biomarker baseline levels and treatment
duration, there was no signiﬁcant difference between treat-
ment groups in the reductions observed for these biomarkers.
F1.2 levels slightly increased in the rivaroxaban group from
baseline to end of treatment, whichwas signiﬁcantly different
from the VKA treatment arm, in which F1.2 levels decreased
(rivaroxaban: 2.7% [95% conﬁdence interval (CI): 5.6 to
11.7%]; VKA: 53% [95% CI: 58.1 to 47.3%]; p<0.001).
Factors Inﬂuencing Changes in Biomarker Levels from
Baseline to the End of Treatment
Pretreatment with OACs
After adjusting for baseline levels of each biomarker and the
duration of treatment, there was a signiﬁcant association
between pretreatment with OACs and changes from baseline
to the end of treatment in the levels of D-dimer (p<0.001,
►Table 3) and F1.2 (p¼0.002, ►Table 3). No signiﬁcant
association was found between pretreatment with OACs
and changes from baseline to the end of treatment in levels
of hs-CRP, hs-IL-6, or TAT. The impact of pretreatment with
OACs on the changes from baseline to the end of treatment in
biomarker levels did not differ signiﬁcantly with regard to
treatment with rivaroxaban or VKA. As summarized
in ►Table 3, in the rivaroxaban group, D-dimer levels
decreased from baseline by 36.0% in patients who were
untreated or naive to OACs and by 23.1% in patients who
had received pretreatment with OACs. In the VKA group,
D-dimer levels decreased from baseline by 42.6% (patients
untreated or naive to OACs) and by 23.4% (patients pre-
treated with OACs). In the rivaroxaban group, F1.2 levels
remained nearly unchanged (patients untreated or naive to
OACs) or increased by 15% (patients pretreated with OACs).
In the VKA group, F1.2 levels decreased by 58.7% (patients
untreated or naive to OACs) and by 36.8% (patients
pretreated with OACs). With the exception of F1.2, there
were no signiﬁcant differences between the treatment arms
(►Table 3).
Fig. 3 Inﬂuence of a history of congestive HF on hs-CRP levels at
baseline. HF, heart failure; hs-CRP, high-sensitivity C-reactive protein;
LLOQ, lower limit of quantiﬁcation; OAC, oral anticoagulant.
Note:Upper linesof theboxdenotetheupperquartiles,midlinesdenotethe
medians and lower lines denote the lower quartiles; crosses denote the
geometric means, and upper and lower lines denote maximum and
minimum values, excluding outliers (i.e., values that are >1.5 times the
interquartile range further apart from the box).
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History of Congestive HF
After adjusting for baseline levels of each biomarker and
treatment duration, in the rivaroxaban group, there was a
signiﬁcant association between a history of congestive HF and
changes in levels of F1.2 from baseline to the end of treatment
(p¼0.033, ►Table 3). In the rivaroxaban group, F1.2 levels
were increased by 9.6% in patientswith a history of congestive
HF, and by1.4% in thosewithnohistoryof congestiveHF. In the
VKA group, F1.2 levels decreased from baseline by 27.6% in
those with a history of congestive HF and by 55.8% in patients
with no history of congestive HF (►Table 3).
Type of AF
After adjusting for baseline levels and treatment duration,
there was a signiﬁcant difference between the treatment
arms in hs-CRP changes in patients with a ﬁrst-diagnosed AF
(rivaroxaban: 5.5% [95% CI: 19.6% to 11.1%; VKA: 37.2%
[95% CI: 51.0 to 19.6%; p¼0.007; ►Table 3).
Nosigniﬁcant relationshipbetween thechanges inbiomark-
er levels and the cardioversion success or the cardioversion
strategy was found after adjusting for differences in baseline
levels and treatment duration (►Supplementary Table S9).
Discussion
The X-VeRT post hoc analyses have demonstrated that, in
patients with AF undergoing planned cardioversion, anti-
coagulation with rivaroxaban is associated with a reduction
in levels of key biomarkers of both coagulation (D-dimer and
TAT) and inﬂammation (hs-IL-6 and hs-CRP). The results
were similar to those observed in the VKA group. In addition,
F1.2 levels were lower in VKA-treated patients than rivarox-
aban-treated patients. These results, therefore, conﬁrm the
expected pharmacodynamic effects of rivaroxaban in this
patient population.
The observed reductions in biomarkers of both coagula-
tion and inﬂammation highlight the important bidirectional
link between coagulation and inﬂammation and support
other data demonstrating the potential of rivaroxaban and
possibly of VKAs to have anti-inﬂammatory effects in
Fig. 4 Inﬂuence of type of AF on levels of D-dimer at baseline. AF, atrial ﬁbrillation; FEU, ﬁbrinogen equivalent units; LLOQ, lower limit of
quantiﬁcation; OAC, oral anticoagulant. Note: Upper lines of the box denote the upper quartiles, mid-lines denote the medians and lower lines
denote the lower quartiles; crosses denote the geometric means, and upper and lower lines denote maximum and minimum values, excluding
outliers (i.e., values that are >1.5 times the interquartile range further apart from the box).
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addition to their anticoagulant actions.22–26 The decrease of
the mentioned biomarkers during rivaroxaban treatment
has also been shown in a similar study in AF.16 Here, von
Willebrand’s factor (vWF) and plasminogen activator inhibi-
tor-1 were measured at baseline and after 6 weeks of
treatment in addition to the biomarkers described here.
The hs-CRP, D-dimer, vWF, and TAT showed a signiﬁcant
decrease in the mean levels from baseline to end of treat-
ment with rivaroxaban. Although it is already well estab-
lished that inﬂammation leads to activation of the
coagulation cascade,27–29 there has been recent focus on
the coagulation cascade triggering the activation of inﬂam-
matory pathways. Thrombin, factor Xa, and ﬁbrin all stimu-
late the production of the proinﬂammatory cytokines IL-6
and IL-8,22,27,30 and treatment with enoxaparin has been
associatedwith a reduction in hs-CRP levels from baseline in
patients with AF who underwent cardioversion.13
In addition to data indicating a role for inﬂammation in the
pathogenesis of AF,8–11 there is evidence suggesting that
inﬂammation can be a consequence of AF.31–33 It is, therefore,
possible that the reduction in inﬂammatory biomarkers
observed in this substudy was, in part, a consequence of the
restorationof sinus rhythmafter cardioversion. In a small study
of patients with persistent AF, hs-CRP levels in patients who
remained in sinus rhythm after cardioversion gradually
decreased and were signiﬁcantly lower at the ﬁnal evaluation
than at baseline before cardioversion; hs-CRP levels did not
change signiﬁcantly in patients with AF recurrence.32 These
data are not supported, however, by a larger studyona range of
inﬂammatory biomarkers before and after cardioversion.34
Overall, it is unlikely that an effect of successful cardioversion
accounts for the entirety of the reductions observed in this
study.
AF is associated with a prothrombotic state,6 and induces
venous stasis and elevated venous pressure, which is thought
to subsequently lead to abnormal changes in blood constitu-
ents, leading to hemostatic and platelet activation, as well as
inﬂammation, and growth factor changes.8 However, it has
previously been demonstrated that levels of D-dimer remain
elevated even after successful cardioversion.35 Furthermore,
rivaroxaban treatment has been associatedwith reductions in
D-dimer, TAT, and F1.2 levels in treatment-naive patientswith
AF,36,37 suggesting that it is possible that at least some of the
effects of rivaroxabanon thesebiomarkers in the current study
are mediated by anticoagulant effects.
The effects of pretreatment with OACs on baseline levels of
D-dimer and F1.2 are in agreement with other observations
and, given the mechanism of action of these drugs, are as
expected.38 The mean reduction in levels of D-dimer and F1.2
in response to treatment with rivaroxaban or a VKA was
Table 2 Results of multivariate models for bleeding events, cardioversion success and time to cardioversion by biomarker baseline
levels, and demographic and clinical covariates
Event n Parametera Effect OR 95% CI p-Value
Logistic models
Bleeding event (yes/no) 828 (96 cases) Log hs-CRP 0.12 1.13 0.96–1.33 0.153
Prior stroke¼ yes 0.74 2.10 0.80–5.54 0.134
Prior TIA¼ yes 0.71 2.03 0.78–5.32 0.149
Cardioversion
success (yes/no)
693 (594 cases) History of diabetes mellitus¼ yes 0.54 0.58 0.34–0.98 0.042
Treatment¼ rivaroxaban 0.59 1.81 1.16–2.82 0.009
Race¼Asian 1.08 0.34 0.19–0.63 0.001
Race¼Black 1.28 0.28 0.07–1.12 0.072
Race¼Other 0.96 0.38 0.13–1.13 0.082
Endpoint n Parametera Effect 95% CI p-Value
Linear model
Log time to ﬁrst
cardioversion under
treatment
693 Log hs-CRP 0.05 0.02–0.09 0.004
Log hs-IL-6 0.12 0.18 to 0.06 <0.001
Log F1.2 0.09 0.05–0.13 <0.001
Log TAT 0.06 0.10 to 0.02 0.003
History of arterial hypertension¼ yes 0.05 0.13 to 0.02 0.167
History of diabetes mellitus¼ yes 0.08 0.17 to 0.02 0.101
Prior myocardial infarction¼ yes 0.18 0.04–0.32 0.012
Treatment¼ rivaroxaban 0.17 0.24 to 0.10 <0.001
Cardioversion strategy¼Delayed 2.49 2.42–2.56 <0.001
Abbreviations: CI, conﬁdence interval; F1.2, prothrombin fragment 1þ 2; HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6,
high-sensitivity interleukin-6; OR, odds ratio; TAT, thrombin–anti-thrombin III complex; TIA, transient ischemic attack.
aParameter combination chosen by stepwise AIC (Akaike’s information criterion) forward selection.
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signiﬁcantly smaller in patients who had received pretreat-
ment with OACs than in patientswhowere untreated or naive
to OACs. Pretreatment with OACs, therefore, needs to be
considered when measuring selected coagulation biomarkers
at baseline.
Treatment with a VKA, but not with rivaroxaban, was
associated with a reduction from baseline in levels of F1.2 in
the present study. It appears that this biomarker might be
differently sensitive to both treatment regimens. One hypoth-
esis is that thismay be related to the different pharmacokinetic
proﬁles of rivaroxaban and VKAs in terms of interaction with
the kinetics of F1.2, which is a marker of thrombin activation.
Forexample, themeanhalf-lifeof rivaroxaban isapproximately
5 to 13hours, whereas the mean half-life of warfarin is
approximately 40hours.39,40 It has been hypothesized that
different effects of rivaroxaban and warfarin on F1.2 levels
and, therefore, on thrombin generation at steady-state might
be associated with differences in the safety proﬁles of the two
drugs.41 For example, compared with warfarin, rivaroxaban,
and other NOACs are associated with lower rates of intracere-
bral hemorrhage (ICH) and better outcomes (e.g., hematoma
expansion) after ICH.42–44 The lower F1.2 levels in patients
receiving warfarin versus rivaroxaban could provide a possible
explanation for this clinical difference. Further studies, ideally
relating ICH outcomes to F1.2 levels, are needed to test this.
There is increasing evidence that inﬂammatory mediators
playan important role inthedevelopmentofcongestiveHF.45 In
patients with HF, the immune system is chronically activated,
with increased circulating levels of the proinﬂammatory cyto-
kines tumor necrosis factor, IL-1 and IL-6 in both ischemic and
Fig. 5 Relative changes of biomarker levels from baseline to the end of treatment, model-adjusted for biomarker baseline level, and treatment
duration. F1.2, prothrombin fragment 1þ 2; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6, high-sensitivity interleukin-6; TAT, thrombin–
anti-thrombin III complex; VKA, vitamin-K antagonist.
Note: Upper lines of the box denote the upper quartiles, mid-lines denote the medians and lower lines denote the lower quartiles; crosses denote
the geometric means, and upper and lower lines denote maximum and minimum values, excluding outliers (i.e., values that are >1.5 times the
interquartile range further apart from the box).
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nonischemic HF.46 Elevated levels of CRP have also been
associated with high mortality and high rates of readmission
in patients with HF.47 The elevated baseline levels of the
inﬂammatory biomarkers hs-CRP and hs-IL-6 observed in
patients with a history of congestive HF in this study are
consistent with anunderlying inﬂammatory state in this group
ofpatients.Given thatF1.2 isaknownbiomarkerofcoagulation,
it was expected that patients with a history of congestive HF
would have higher F1.2 levels at baseline than those without a
history of congestive HF, but this was not observed.
The observation that patients with newly diagnosed AF had
higher D-dimer levels at baseline than patients with long-
standing AF was unexpected because long-standing AF is
thought to be associatedwitha prothrombotic state andhigher
levels of D-dimer than acute AF.48 However, recent large
observational studies have demonstrated that acute-onset AF
is associated with a higher risk of stroke than long-standing
AF,49 and elevated levels of D-dimer have also been associated
with an increased risk of stroke in patients with AF.50,51 Our
ﬁndings are consistent with these observations and demon-
strate that disease effects need to be consideredwhen evaluat-
ing biomarkers. In addition, thehigher D-dimer levelsmight be
related to less prior use of OACs in patients with newly
diagnosed AF than in patients with long-standing AF.
Also unexpectedwere the decreased hs-IL-6 and F1.2 levels
in patients with long-standing AF. It has been described that
long duration of AF is associated with high–hs-CRP levels and
large–left atrial dimensions, supporting a link between the
burden of AF, inﬂammation, and structural remodeling.52 IL-6
physiologically stimulates thesynthesisof several acute-phase
reaction proteins, such as CRP, so that one would also expect
increased IL-6 levels in long-standing AF. However, the ﬁnd-
ings in this study show the opposite effect regarding IL-6 and
no relevant effect on hs-CRP. The pretreatment with OACs did
not signiﬁcantly inﬂuence baseline levels of hs-IL-6, so this
cannot explain theseﬁndings regardinghs-IL-6; however, F1.2
and D-dimer levels seem to be affected by prior OAC intake.
Further studies need to be done to explain or to conﬁrm these
ﬁndings.
None of the biomarkers showed any prognostic or predic-
tive value with regard to bleeding events or the probability
for cardioversion success. Baseline levels of all biomarkers
except D-dimer were signiﬁcantly associated with time to
cardioversion. However, effect sizes were small, and no
discriminatory power of the biomarkers was detected. In
the X-TRA biomarker substudy, high levels of inﬂammatory
biomarkers in patients with AF who had left atrial/left atrial
appendage thrombus were associated with the thrombus
being completely resolved or reduced with rivaroxaban
treatment and, therefore, also showed potential as predictive
biomarkers.16 These correlates require additional investiga-
tion to assess their clinical utility.
A key strength of the present analyses was the large sample
size. In some cases, even small changes in biomarker levels
were found to be statistically signiﬁcant. However, it has to be
noted that, even though a large number of analyses were
performed, no formal adjustment for multiple testing was
performed owing to the exploratory nature of the analyses.
Thus, when interpreting the results, the potential for false-
positive results due to multiplicity must be considered. More-
over, owing to the post hoc nature of the analyses and the fact
that biomarkers were only collected from a subset of the total
study population, it has to be noted that balance between the
two treatment groups with regard to demographics, clinical
variables, and biomarker baseline levels was not ensured
(summary of baseline characteristics: ►Supplementary
Table S2). All analyses of biomarker changes from baseline to
endof treatmentwereadjustedforbiomarker levelsatbaseline,
making it unlikely that a regression to themean effect explains
the reduction in biomarker levels that was observed from
baseline to the end of treatment.
Conclusion
In conclusion, treatmentwith rivaroxabanor aVKA resulted in
a signiﬁcant reduction from baseline in levels of biomarkers of
coagulation (D-dimer andTAT) and inﬂammation (hs-IL-6 and
hs-CRP), with no signiﬁcant difference between treatment
groups. F1.2 levels were reduced from baseline in patients
randomized to receive a VKA but not in those randomized to
receive rivaroxaban, providing hypothesis-generating insights
into the possible mechanisms driving the safety differences
between VKAs and rivaroxaban. The results presented here
also highlight the need to consider pretreatment with OACs
and clinical factors (e.g., type of AF and history of congestive
HF) when evaluating biomarkers of coagulation and inﬂam-
mation, and invite further investigation to conﬁrm the poten-
tial prognostic or predictive value of these biomarkers in
patients with AF.
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